

# Discovering translational biomarkers in neurodevelopmental disorders

---

*Mustafa Sahin, Stephanie R. Jones, John A. Sweeney, Elizabeth Berry-Kravis, Barry W. Connors, Joshua B. Ewen, Adam L. Hartman, April R. Levin, William Z. Potter and Laura A. Mamounas, on behalf of the Biomarker Workshop Faculty*

<https://doi.org/10.1038/d41573-018-00010-7>

## Supplementary Box 1 | Workshop speakers, working group members and affiliations

- E. Martina Bebin, University of Alabama, Birmingham, Alabama, USA
- Audrey C. Brumback, Dell Medical School at the University of Texas at Austin, Neurology Department, Austin, Texas, USA
- Bettina Buhning, National Institute of Mental Health, Bethesda, Maryland, USA
- Arthur Combs, MC 10, Inc., Lexington, Massachusetts, USA
- Craig A. Erickson, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
- Lauren E. Ethridge, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
- Michela Fagiolini, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA
- André Fenton, New York University, New York, New York, USA
- Jennifer Foss-Feig, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Flavio Frohlich, University of North Carolina, Chapel Hill, North Carolina, USA
- Jay Gibson, UT Southwestern Medical Center, Dallas, Texas, USA
- Heather Hazlett, University of North Carolina, Chapel Hill, North Carolina, USA
- David R. Hessel, University of California Davis MIND Institute, Sacramento, California, USA
- Shafali S. Jeste, UCLA David Geffen School of Medicine, Los Angeles, California, USA
- David M. Katz, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
- Tal Kenet, Massachusetts General Hospital, Boston, Massachusetts, USA
- Darcy A. Krueger, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
- Jason Lerch, The Hospital for Sick Children and The University of Toronto, Canada
- Gregory Light, University of California, San Diego, California, USA
- Beatriz Luna, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
- Mirjana Maletic-Savatic, Baylor College of Medicine and Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, Texas, USA
- Eric Marsh, Children's Hospital of Philadelphia & University of Pennsylvania, Philadelphia, Pennsylvania, USA
- David McCormick, University of Oregon, Eugene, Oregon, USA
- James C. McPartland, Yale Child Study Center, New Haven, Connecticut, USA
- Michael Milham, Child Mind Institute, New York, New York, USA
- Meera Modi, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA
- Matthew W. Mosconi, University of Kansas, Lawrence, KS, USA
- Declan Murphy, King's College, London, UK
- Charles A. Nelson III, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA
- Jeff L. Neul, Vanderbilt University Medical Center, Nashville, Tennessee, USA
- Lindsay M. Oberman, Uniformed Services University of Health Sciences, Bethesda, Maryland, USA
- Gahan Pandina, Janssen Research & Development, LLC, Titusville, New Jersey, USA
- Ernest Pedapati, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
- Benjamin D. Philpot, University of North Carolina, Chapel Hill, North Carolina, USA
- Joseph Piven, University of North Carolina, Chapel Hill, North Carolina, USA
- John R. Pruett, Jr., Washington University School of Medicine, St. Louis, Missouri, USA
- Khaleel A. Razak, University of California, Riverside, California, USA
- Michael E. Ragozzino, University of Illinois at Chicago, Chicago, Illinois, USA
- Timothy P.L. Roberts, Children's Hospital of Philadelphia & University of Pennsylvania, Philadelphia, Pennsylvania, USA
- Alexander Rotenberg, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA
- Rodney C. Samaco, Baylor College of Medicine and Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, Texas, USA
- Charlie Schroeder, Columbia University Medical Center, New York, New York, USA
- Krish Singh, Cardiff University, Cardiff, UK
- Daniel Tarquinio, Center for Rare Neurological Diseases, Atlanta, Georgia, USA
- Craig Tenke (deceased) Columbia University Medical Center, New York, New York, USA
- Brian Theyel, Brown University and Alpert Medical School, Providence, Rhode Island, USA
- Simon K. Warfield, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA
- Sara J. Webb, Seattle Children's Research Institute & University of Washington, Seattle, Washington, USA
- Ling Wong, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA

## Supplementary Box 2 | Competing interests statement

- Mustafa Sahin reports grant support from Novartis, Roche, Pfizer, Ipsen, LAM Therapeutics and Quadrant Biosciences. He has served on scientific advisory boards for Sage, Roche and Takeda.
- Elizabeth Berry-Kravis has been a consultant for Seaside Therapeutics, Novartis, Roche, Alcobra, Neuren, Cydan, Fulcrum, GW, Neurotrope, Marinus, Zynerba, BioMarin and Ovid Pharmaceuticals; a consultant for Novartis, Roche and Neurotrope regarding the conduct of clinical trials in fragile X syndrome (FXS) and other rare neurological diseases; on the scientific advisory board for Vteese/Mallinckrodt to provide guidance on clinical trials in Niemann–Pick type C (NP-C) disease; and has received research funding to conduct clinical trials in FXS and/or other neurodevelopmental disorders from Novartis, Roche, Seaside Therapeutics, Alcobra and Neuren, from Ovid and Zynerba to conduct a clinical trial in NP-C, from Vtesse/Mallinckrodt and from Asuragen to develop fragile X mental retardation 1 testing standards.
- William Z. Potter has served on advisory boards to Eli Lilly, Takeda, Astellas, Praxis and Noven and holds Merck & Co. stock.
- Arthur Combs is an employee and officer of MC10.
- Lauren Ethridge has served as a consultant to Ovid, Fulcrum and Novartis for work in FXS and Phelan McDermid syndrome.
- André Fenton is a founder of Bio-Signal Group Corp.
- Flavio Frohlich is the lead inventor of intellectual property (IP) filed by the University of North Carolina. The clinical studies performed in the Frohlich Lab have originally received a designation as conflict of interest with administrative considerations that was subsequently removed. Frohlich is the founder, chief scientific officer and majority owner of Pulvinar Neuro LLC. The company played no role in this workshop. Flavio Frohlich is also an author with Elsevier and receives royalty payments.
- David R. Hessel has served as a consultant to Ovid and Zynerba regarding FXS clinical trials.
- Shafali S. Jeste has served as a consultant to Roche.
- Darcy A. Krueger has received consulting fees from Novartis and Upsher-Smith and additional research support from Novartis.
- Gregory Light has been a consultant to Astellas, Boehringer Ingelheim, Dart NeuroScience, Heptares, Lundbeck, Merck & Co., NeuroSig and Takeda.
- Eric Marsh has been a site principal investigator for studies from GW Pharma, Neuren, Zogenix, Ovid and Marinus.
- Matthew W. Mosconi has served as a consultant on an investigator-initiated study of Phelan McDermid syndrome supported by Novartis.
- Declan Murphy has served on an advisory board to Roche.
- Gahan Pandina is an employee of Janssen Research & Development and is a Johnson & Johnson stockholder.
- Joseph Piven is the editor of the *Journal of Neurodevelopmental Disorders*, Springer Nature.
- Alexander Rotenberg has received research support from Brainsway, CREmedical, Nexstim, Neuroelectrics, Roche, Sage and Takeda.
- Timothy Roberts has been on consulting and /or advisory board positions with CTF, Ricoh and Spago, has IP licensing arrangements with MEGIN and has stock options in Prism Clinical Imaging